Barely Significant
← all excerpts

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.

J Headache Pain · 2019 · PMC6734267 · PMID 31159727

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
Headache hours, days with severe headache intensity (defined as pain ≥7/10 on a numeric analog scale), days with acute headache medication use and days with triptan use showed a trend to increase over time after trial termination but were still numerically lower than baseline at all examined time points (Table 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.